Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs),

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback is a buy-the-dip opportunity.

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven platform.

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced return prospects. See more.

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study,

Daiwa analyst Narumi Nakagiri downgraded Eli Lilly (LLY) to Neutral from Outperform with a $700 price target Published first on TheFly – the

Wall Street’s major averages ended mostly lower on Friday, as market participants have been keeping an eye on the highly anticipated meeting between Donald Trump and Vladimir Putin. However, the S&P 500 Health Care Index Sector (NYSEARCA:XLV) gained about 2.